PK
Agios’ Pyrukynd Misses Primary Endpoint in First Pediatric Study for Rare Blood Disorder
Agios Pharmaceuticals, Pyrukynd, mitapivat, PK deficiency, pediatric study, blood disorder, Phase 3 ACTIVATE-KidsT study
Takeda Appoints Former CRISPR CMO Phuong Khanh (PK) Morrow to Lead Oncology R&D Amidst Pipeline Pruning
Clustered Regularly Interspaced Short Palindromic Repeats, PK